Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?

• Published in: Endocrinology and metabolism (Seoul) Vol. 37; no. 3; pp. 415 - 429
• Main Author: Rhee, Eun-Jung
• Format: Journal Article
• Language: English
• Published: Korea (South) Korean Endocrine Society 01.06.2022; 대한내분비학회
• Subjects: Blood Glucose; cardiovascular diseases; Diabetes Mellitus; diabetic nephropathies; heart failure; Humans; Hyperglycemia - prevention & control; Insulin; Life Style; medication therapy management; osteoporosis; Review; stroke; 내과학; Heart failure; Osteoporosis; Stroke; Diabetes mellitus; Diabetic nephropathies; Medication therapy management; Cardiovascular diseases
• ISSN: 2093-596X; 2093-5978; 2093-5978
• DOI: 10.3803/EnM.2022.304

The world is suffering from a rapid increase in the number of people with diabetes due to the increased prevalence of obesity and lengthened life span. Since the development of insulin thanks to the efforts of Prof. Banting and Dr. Best in 1922, for which they won the Nobel Prize, remarkable developments in anti-diabetic medications have dramatically lengthened the lifespan of patients with diabetes. However, the control rate of hyperglycemia in patients with diabetes remains unsatisfactory, since glycemic control requires both medication and lifestyle modifications to slow the deterioration of pancreatic beta-cell function and prevent diabetic complications. From the initial "triumvirate" to the "ominous octet," and now the "egregious eleven," the number of organs recognized as being involved in hyperglycemia and diabetes has increased with the development of anti-diabetic medications. Recent unexpected results from outcome trials of anti-diabetic medications have enabled anti-diabetic medications to be indicated for the prevention of chronic kidney disease and heart failure, even in patients without diabetes. In this review, I would like to summarize the extra-glycemic effects of anti-diabetic medications.